Olumiant® (Baricitinib)

Para consultar la información para prescribir completa de Olumiant® (Baricitinib) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Baricitinib: Formulation

Baricitinib is supplied as debossed, film-coated, immediate-release tablets available in 2 or 4 mg.

MX_cFAQ_BAR019_HOW_SUPPLIED_RA
MX_cFAQ_BAR019_HOW_SUPPLIED_RA
es-MX

The information contained in this letter may not completely match the current local labeling for BARICITINIB. Please see local labeling approved in your country.

Description of Baricitinib Tablet

Each tablet has a recessed area on both sides of the tablet surface to facilitate its use.1

Baricitinib 2-mg tablets are light pink in color and oblong in shape with a “Lilly” designation on one side and a “2” designation on the other side of the tablet surface.1

Baricitinib 4-mg tablets are medium pink in color and round in shape with a “Lilly” designation on one side and a “4” designation on the other side of the tablet surface.1

Description of Baricitinib Packaging

Baricitinib tablets are available in

  • 14, 28, 35, 56, 84, and 98 film-coated tablets in plastic film blisters sealed with an aluminum foil, and
  • 28 and 84 film-coated tablets in aluminum perforated unit dose blisters.2

References

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Fecha de la última revisión: 2019 M05 17


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta